79
Participants
Start Date
December 29, 2020
Primary Completion Date
November 18, 2022
Study Completion Date
December 21, 2022
Placebo
LX9211 matching-placebo, tablets will be administered orally.
LX9211
LX9211, 200 mg, tablets will be administered orally.
Lexicon Investigational Site (137), Prague
Lexicon Investigational Site (141), Prague
Lexicon Investigational Site (135), Prague
Lexicon Investigational Site, Jenkintown
Lexicon Investigational Site (148), Cary
Lexicon Investigational Site (147), Marietta
Lexicon Investigational Site, Ormond Beach
Lexicon Investigational Site, Winter Park
Lexicon Investigational Site (113), Miami
Lexicon Investigational Site, Miami
Lexicon Investigational Site, Miami
Lexicon Investigational Site, Brandon
Lexicon Investigational Site, Canton
Lexicon Investigational Site (140), Pardubice
Lexicon Investigational Site, Kenosha
Lexicon Investigational Site, Wauconda
Lexicon Investigational Site, Flossmoor
Lexicon Investigational Site, Hazelwood
Lexicon Investigational Site, Baytown
Lexicon Investigational Site, Victoria
Lexicon Investigational Site, Salt Lake City
Lexicon Investigational Site, Scottsdale
Lexicon Investigational Site, Tucson
Lexicon Investigational Site, Albuquerque
Lexicon Investigational Site, Greenbrae
Lexicon Investigational Site, Boston
Lexicon Investigational Site (138), Choceň
Lexicon Investigational Site (136), Prague
Lexicon Investigational Site (128), Katowice
Lexicon Investigational Site (130), Katowice
Lexicon Investigational Site (134), Lublin
Lexicon Investigational Site (133), Warsaw
Lead Sponsor
Lexicon Pharmaceuticals
INDUSTRY